Affimed Stock Price, News & Analysis

Affimed N.V. (Nasdaq: AFMD) will release its third quarter 2022 results and corporate update on November 15, 2022, followed by a conference call at 8:30 a.m. EST / 14:30 CET. Investors can join via phone or through a webcast available on the company’s website. The call features the latest updates on Affimed’s immuno-oncology initiatives and its ROCK^® platform designed to combat various cancers by utilizing the innate immune system. A replay will be accessible for 30 days post-call.

Affimed and Artiva have announced a strategic partnership to develop a combination therapy targeting CD30-positive lymphoma patients. This collaboration will utilize Affimed's AFM13 and Artiva's AB-101, which has shown impressive response rates in clinical studies. The investigational new drug submission to the FDA is expected in the first half of 2023. Affimed will retain 67% of the revenue generated from the therapy, while Artiva will receive 33%. This partnership builds on two years of preclinical research and aims to expedite treatment for patients with significant unmet medical needs.

Affimed announced promising results from its ongoing phase 1/2 trial of AFM13 combined with allogeneic NK cells for CD30-positive lymphoma patients. Among 24 patients, the treatment achieved a 100% overall response rate and a 70.8% complete response rate. Patients tolerated the treatment well, receiving up to four cycles. Further details will be presented on December 10, 2022, during the ASH Annual Meeting. Additionally, preclinical data for AFM28 highlights its potential efficacy against CD123-positive leukemic cells, set to be presented on December 12, 2022.

Affimed N.V. (Nasdaq: AFMD) announced its CEO, Dr. Adi Hoess, will present at the 2022 Jefferies London Healthcare Conference on November 16, 2022, at 12:55 p.m. GMT. A live webcast will be available on the company's website, with a replay accessible for 30 days post-event. Affimed is a clinical-stage immuno-oncology firm focused on enhancing patients' immune responses against cancer through its innovative ROCK® platform. The company aims to utilize the innate immune system to combat various tumors, showcasing a strong commitment to cancer research.

Affimed N.V. (Nasdaq: AFMD) has announced the acceptance of two abstracts showcasing new data on their innate cell engager (ICE®) AFM24 at the 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) in Boston, scheduled for November 8-12, 2022. The first poster will detail findings from a phase 1 study of AFM24 monotherapy, while the second will present initial results from a phase 1 dose escalation study of AFM24 in combination with Roche’s atezolizumab. AFM24 targets EGFR-expressing solid tumors and is part of Affimed's innovative cancer treatment approach.

Affimed N.V. (Nasdaq: AFMD) announced the phase 1 data on its innate cell engager AFM24 at the ESMO Congress. The recommended phase 2 dose (RP2D) was set at 480 mg, with ongoing enrollment in specific disease cohorts. The trial observed stable disease in 10 of 27 evaluable patients, with some patients maintaining stable disease for over four months. The treatment was well tolerated, with no on-study deaths and no maximum tolerated dose reached. AFM24 activates both the innate and adaptive immune systems, marking a significant milestone for its development.

Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company, announced its participation in several investor conferences in September 2022. Key events include:

• Wells Fargo Healthcare Conference on September 7, 2022, at 3:10 p.m. EDT in Boston, MA, with a webcast available.
• Citi’s Annual BioPharma Virtual Conference on September 8, 2022, for one-on-one meetings in Boston, MA.
• Morgan Stanley’s Global Healthcare Conference on September 13, 2022, for one-on-one meetings in New York, NY.
• Jefferies Cell and Genetic Medicine Summit on September 29, 2022, for one-on-one meetings in New York, NY.

Affimed (AFMD) reported second quarter 2022 financial results, revealing a net loss of €19.4 million, or €0.13 per share, compared to a loss of €18.8 million, or €0.16 per share, in Q2 2021. Cash and cash equivalents stood at €237.2 million as of June 30, 2022, with a runway into mid-2024. The company is on track to release data from its AFM13 monotherapy REDIRECT trial and ongoing studies for AFM24 and AFM28. Research and development expenses decreased by 4% year-over-year, while general administrative expenses surged by 54%. A conference call to discuss results is scheduled for August 11, 2022.

Affimed N.V. (Nasdaq: AFMD) will release its second quarter 2022 financial results and corporate updates on August 11, 2022. The presentation will be followed by a conference call at 8:30 a.m. EDT, accessible via phone or webcast. Affimed focuses on harnessing the innate immune system to fight cancer, featuring its proprietary ROCK® platform which creates innovative innate cell engager (ICE®) molecules. This approach positions Affimed as a pioneer in clinical-stage ICE® development.